0001958489
Company
Cortigent, Inc.
Electromedical & Electrotherapeutic Apparatus · CRGT
ipo
amended
NYSE American
S-1/A
Filing Timeline
SEC EDGAR
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. is conducting an initial public offering (IPO) of 1.5 million shares of common stock at $10.00 per share, aiming to list on NYSE American under the symbol CRGT. The company, previously part of Vivani Medical, Inc., will remain a controlled company post-IPO due to Vivani's 77% voting stake. Cortigent is an emerging growth company with a focus on neurostimulation technologies for artificial vision (Orion) and stroke recovery, both requiring FDA approval. The filing highlights risks related to clinical trial outcomes, regulatory hurdles, and dependence on Vivani.
2026-03-17 · 0001753926-26-000480
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. is conducting an initial public offering (IPO) of 1,500,000 shares of common stock at $10.00 per share, with an expected listing on NYSE American under the symbol CRGT. The company, a pioneer in neurostimulation devices for stroke recovery and artificial vision, is a controlled company following the offering, with Vivani Medical, Inc. retaining 77% of voting power. The IPO follows a 20-year history of developing neurostimulation technologies, including the Argus II system for artificial vision and the Orion system for treating blindness, both requiring FDA approval. The offering includes a 45-day underwriter option to purchase additional shares.
2026-03-03 · 0001753926-26-000427
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. filed an updated S-1/A registration statement for its initial public offering (IPO), reflecting revisions to the prospectus date and underwriter delivery timelines. The filing emphasizes the company's neurostimulation technologies for artificial vision (Orion) and stroke recovery, both requiring FDA approval. The company remains a controlled entity under NYSE rules due to Vivani Medical, Inc.'s majority ownership post-offering. Key financial details include a $10.00 per-share offering price and a 45-day underwriter over-allotment option.
2026-01-09 · 0001753926-26-000085
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. is conducting an initial public offering (IPO) of 1,500,000 shares of common stock at $10.00 per share, aiming to list on NYSE American under the symbol CRGT. The company, previously part of Vivani Medical, Inc., focuses on neurostimulation technologies for artificial vision (Orion) and stroke recovery. Post-IPO, Vivani will retain ~77% of voting power, making Cortigent a controlled company under NYSE rules. The offering includes a 45-day over-allotment option, with proceeds intended for clinical trials, product development, and general operations.
2025-12-02 · 0001753926-25-001850
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows FWP and supplements the active offering with updated prospectus details.
Cortigent, Inc. focuses on neurostimulation technologies for artificial vision and stroke recovery. The current filing outlines an IPO offering 1.5 million shares at $10.00 each, with proceeds targeting research, clinical trials, and device development. The company highlights its FDA-approved Argus II system, next-generation Orion device with Breakthrough Device designation, and a stroke recovery system in early development. Key priorities include securing FDA approvals, expanding market reach, and leveraging its intellectual property estate.
2024-12-11 · 0001753926-24-002063
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior FWP filing.
Cortigent, Inc. is conducting an IPO of 1.5 million common shares at $10.00 per share, with proceeds intended for research, commercialization of its Orion artificial vision system, stroke recovery device development, repaying Vivani Medical, and working capital. The company, a controlled company under NYSE rules due to Vivani's 77% ownership, focuses on neurostimulation technologies for artificial vision and stroke recovery. Its Argus II device, FDA-approved for rare blindness, is no longer sold as resources shift to Orion and stroke applications. The offering includes a 45-day underwriter option for additional shares.
2024-12-11 · 0001753926-24-002059
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows S-1/A and supplements the active offering with updated prospectus details.
Cortigent, Inc. is conducting an IPO with an offering of 1.5 million common shares at $10.00 per share, aiming to raise $15 million. The proceeds will fund Orion system research, commercialization, stroke recovery device development, and repayments to parent company Vivani. The company focuses on neurostimulation technologies for artificial vision (Orion) and stroke recovery, with FDA Breakthrough Device designation for Orion. The filing highlights clinical trial progress, intellectual property, and market potential for both applications.
2024-11-27 · 0001753926-24-002004
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior FWP filing.
Cortigent, Inc. is conducting an IPO with 1.5 million common shares at $10.00 per share, aiming to list on Nasdaq under the symbol CRGT. The offering follows a separation from parent company Vivani Medical, Inc., which will retain 77% voting control post-offering, making Cortigent a controlled company under Nasdaq rules. The company focuses on neurostimulation technologies for artificial vision (Argus II, Orion) and stroke recovery, with both systems in clinical trials. As an emerging growth company, it benefits from reduced reporting requirements but faces risks related to unproven technologies and regulatory approvals.
2024-11-20 · 0001753926-24-001978
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows S-1/A and supplements the active offering with updated prospectus details.
Cortigent, Inc. is a medical technology company focused on precision neurostimulation for artificial vision and stroke recovery. The current filing outlines the proposed IPO of 1.5 million common shares at $10.00 per share, with proceeds intended for clinical research, device development, and operational needs. The company highlights its FDA Breakthrough Device designation for the Orion system and ongoing efforts to advance stroke recovery therapies, while emphasizing its intellectual property and leadership team.
2024-09-05 · 0001753926-24-001546
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior FWP filing.
Cortigent, Inc. is conducting an IPO of 1.5 million common shares at $10.00 per share, aiming to list on Nasdaq under the symbol CRGT. The offering follows the discontinuation of Argus II sales in 2019 to focus on Orion, an advanced artificial vision system, and a stroke recovery neurostimulation platform. Vivani Medical, Inc. will retain 77% ownership post-offering, making Cortigent a controlled company under Nasdaq rules. The filing emphasizes risks related to investigational devices, FDA approval, and market uncertainties.
2024-09-04 · 0001753926-24-001542
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows S-1/A and supplements the active offering with updated prospectus details.
Cortigent, Inc. is offering 1.5 million shares of common stock at $10.00 per share, with proceeds allocated to research, development, and repaying its parent company, Vivani. The company focuses on neurostimulation technologies for artificial vision (Orion system) and stroke recovery, with both systems in clinical trials. The offering highlights its leadership in precision neurostimulation, extensive IP portfolio, and targeted markets estimated at $4-10 billion. The filing includes updated timelines for product development and regulatory submissions.
2024-08-20 · 0001753926-24-001455
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. is conducting an S-1/A amendment for its IPO, offering 1.5 million common shares at $10.00 per share. The company focuses on neurostimulation technologies for artificial vision (Argus II, Orion) and stroke recovery. Vivani Medical, Inc. remains the sole beneficial owner, maintaining 77% voting control post-offering. The filing emphasizes risks related to unproven clinical trials, reliance on Vivani's IP, and controlled company governance. The IPO is contingent on Nasdaq listing approval.
2024-08-16 · 0001753926-24-001447
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. is conducting an initial public offering (IPO) of 1,500,000 shares of common stock at $10.00 per share, aiming to list on Nasdaq under the symbol CRGT. The company focuses on neurostimulation technologies for critical body function recovery, including artificial vision (Argus II, Orion) and stroke rehabilitation. Prior to the IPO, Vivani Medical, Inc. will own 77% of voting power, making Cortigent a controlled company. The offering is contingent on Nasdaq approval, and the company is an emerging growth company with reduced reporting requirements.
2024-06-07 · 0001753926-24-001089
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior FWP filing.
Cortigent, Inc. is conducting an IPO of 1.5 million common shares at $10.00 per share, aiming to list on Nasdaq under the symbol CRGT. The offering includes a 45-day underwriter option for 225,000 additional shares. The company focuses on neurostimulation technologies for artificial vision (Argus II, Orion) and stroke recovery, with Orion designated as an FDA Breakthrough Device. Post-IPO, Vivani Medical, Inc. will hold ~77% of voting power, making Cortigent a controlled company under Nasdaq rules. The filing amends prior disclosures, including underwriting terms and use of proceeds.
2024-05-23 · 0001753926-24-001022
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows S-1/A and supplements the active offering with updated prospectus details.
Cortigent, Inc. is a medical technology company focused on neurostimulation solutions for artificial vision and stroke recovery. The filing outlines an upcoming IPO offering 1.5 million shares at $10.00 per share, with proceeds allocated to clinical research, device commercialization, and repayment of parent company debt. The company emphasizes its FDA-approved Argus II system for artificial vision and its next-generation Orion platform, which has received Breakthrough Device designation. A new stroke recovery system is also in development, leveraging its core neurostimulation technology. The offering is underwritten by ThinkEquity, with anticipated Nasdaq listing under the ticker CRGT.
2024-03-28 · 0001753926-24-000625
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior FWP filing.
Cortigent, Inc. is conducting an IPO for its common stock, with an expected price of $10.00 per share and a target offering size of $15 million. The company focuses on neurostimulation technologies for artificial vision (Argus II, Orion) and stroke recovery, with devices currently in clinical trials. Vivani Medical, Inc. will remain the largest shareholder post-offering, making Cortigent a controlled company under Nasdaq rules. The filing emphasizes risks related to unproven technologies, regulatory hurdles, and reliance on a single shareholder.
2024-03-22 · 0001753926-24-000605
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows S-1/A and supplements the active offering with updated prospectus details.
Cortigent, Inc. is conducting an IPO offering 1.5 million common shares at $10.00 per share, aiming to raise $15 million. The proceeds will fund Orion research, stroke recovery device development, FDA consultations, and repay parent company Vivani. The company focuses on neurostimulation devices for artificial vision (Orion) and stroke recovery, with FDA Breakthrough Device designations. Key products include the Argus II system (discontinued) and investigational Orion and stroke recovery systems targeting large patient populations. Leadership highlights experienced management and a strong IP portfolio.
2024-03-06 · 0001753926-24-000486
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. is conducting an initial public offering (IPO) of 1,500,000 shares of common stock at an anticipated price of $10.00 per share. The company develops targeted neurostimulation systems for artificial vision and stroke recovery, with its Argus II device approved for rare blindness and the Orion system in clinical trials. The IPO follows a 1-for-4 reverse stock split, reducing shares outstanding to 5,000,000. Vivani Medical, Inc. will remain the sole beneficial owner post-offering, maintaining control over 77% of voting power. The company is an emerging growth entity and faces significant risks related to clinical trial outcomes and market adoption.
2024-02-29 · 0001753926-24-000432
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows FWP and supplements the active offering with updated prospectus details.
Cortigent, Inc. is advancing neurostimulation technologies for artificial vision and stroke recovery, with its Orion system in clinical trials and a proposed IPO to fund development. The company seeks to capitalize on FDA Breakthrough Device designations and targets a $10 billion U.S. market for neurostimulation applications. The offering aims to raise $15 million through 1.5 million shares at $10 each, with proceeds allocated to research, clinical trials, and commercialization efforts.
2023-08-28 · 0001753926-23-001141
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior FWP filing.
Cortigent, Inc. is conducting an initial public offering (IPO) of 1,500,000 shares of common stock at $10.00 per share, aiming to list on Nasdaq under the symbol CRGT. The company focuses on developing targeted neurostimulation systems for artificial vision and stroke recovery, with its Argus II device FDA-approved for rare blindness and Orion in clinical trials. The IPO follows a reverse stock split, reducing shares outstanding to 5,000,000, all held by parent company Vivani Medical, Inc. Proceeds will fund research, clinical trials, and commercialization efforts.
2023-08-28 · 0001753926-23-001139
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows FWP and supplements the active offering with updated prospectus details.
Cortigent, Inc. is a neurostimulation company focused on recovering critical body functions through medical devices. The filing outlines a proposed IPO for 1.5 million shares at $10.00 per share, with proceeds earmarked for clinical trials, research, and working capital. Key products include the Argus II artificial vision system (FDA-approved) and the Orion system for treating blindness, alongside a stroke recovery system in development. The company emphasizes its leadership team, FDA Breakthrough Device designations, and potential market opportunities in neurostimulation.
2023-08-04 · 0001753926-23-001002
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows 8-A12B and supplements the active offering with updated prospectus details.
Cortigent, Inc. is preparing for its IPO with a proposed listing on Nasdaq under the ticker CRGT. The offering includes 1.5 million common shares at $10.00 each, with proceeds allocated to clinical trials for its Orion artificial vision system and stroke recovery device, research, and working capital. The company emphasizes its FDA Breakthrough Device designation for Orion and its 20-year history in neurostimulation technology, while highlighting risks related to clinical trial outcomes and regulatory approvals.
2023-06-28 · 0001753926-23-000861
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows S-1/A and registers the class of securities for exchange listing.
Cortigent, Inc. filed Form 8-A12B to register its common stock for listing on Nasdaq, referencing its prior S-1/A registration statement. The filing focuses on securities registration under Section 12(b) of the Exchange Act, incorporating details from the S-1/A prospectus. No new operational or financial details are provided beyond the registration process.
2023-06-08 · 0001753926-23-000792
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. is conducting a firm commitment initial public offering (IPO) of 1,500,000 shares of common stock at an anticipated price of $10.00 per share. The company plans to list on Nasdaq under the symbol CRGT. Prior to the IPO, Vivani Medical, Inc. will own 100% of the shares, but post-offering, Vivani will hold ~77% of voting power. The filing includes details about the reverse stock split, underwriter options, and risks related to investigational devices and reliance on a single shareholder.
2023-06-07 · 0001753926-23-000788
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. is conducting a firm commitment initial public offering (IPO) of its common stock, aiming to list on Nasdaq under the symbol CRGT. The company develops targeted neurostimulation systems for critical body function recovery, including artificial vision (Argus II and Orion) and stroke recovery. The filing highlights ongoing clinical trials for Orion and stroke recovery systems, with a focus on addressing unmet medical needs. The company emphasizes its emerging growth status and the risks associated with its investigational devices.
2023-05-19 · 0001753926-23-000702
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Cortigent, Inc. is conducting a firm commitment initial public offering (IPO) of its common stock, with the goal of listing on Nasdaq under the symbol CRGT. The company, an emerging growth company, focuses on developing targeted neurostimulation systems for artificial vision (Argus II, Orion) and stroke recovery. Prior to the IPO, there has been no public market for its stock. The offering follows amendments to its registration statement, with Vivani Medical, Inc. as the sole beneficial owner pre-offering. The company anticipates listing on Nasdaq, though this is not guaranteed.
2023-05-04 · 0001753926-23-000582
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Cortigent, Inc. is conducting an initial public offering (IPO) of its common stock, with shares anticipated to be listed on Nasdaq under the symbol CRGT. The company, previously part of Vivani Medical, Inc., develops neurostimulation technologies for artificial vision (Argus II, Orion) and stroke recovery. The current S-1/A filing includes updates to risk disclosures, underwriter terms, and details about the controlled company status post-IPO. The offering aims to raise capital for product development and commercialization, with Vivani Medical remaining the sole beneficial owner prior to the offering.
2023-04-18 · 0001753926-23-000467
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
Cortigent, Inc. is conducting an initial public offering (IPO) of its common stock, with no prior public market for its shares. The company focuses on neurostimulation technologies for artificial vision and stroke recovery, including the Argus II and Orion systems. The IPO aims to list on Nasdaq under the symbol CRGT, with Vivani Medical, Inc. as the sole beneficial owner before the offering. The company emphasizes its FDA-approved devices, clinical trials, and potential market growth, while highlighting risks related to regulatory approvals, clinical outcomes, and reliance on a single shareholder.
2023-03-20 · 0001753926-23-000293
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Cortigent, Inc. is conducting an initial public offering (IPO) of its common stock, with shares expected to be listed on Nasdaq under the symbol CRGT. The company develops neurostimulation systems for artificial vision and muscle function restoration, including the Argus II and Orion platforms. Prior to this offering, there has been no public market for its stock. The IPO aims to raise capital for growth, with an anticipated price range of $ to $ per share. The company is an emerging growth company and a controlled company under Nasdaq rules due to single-shareholder ownership. The offering is subject to FDA approvals and market risks.
2023-01-13 · 0001753926-23-000056
Comparable Deals
9 comparable deals
Healthcare & BiotechMicro (<$50M)Last 18 months
Only 0 strict matches; expanded to 9 using nearest neighbors.
Swarmer, Inc
SWMR
similar deal sizerecent IPO
BLOOMIA HOLDINGS, INC.
TULP
similar deal sizerecent IPO
Bimergen Energy Corp
BESS
similar deal sizerecent IPO
MiniMed Group, Inc.
MMED
same SIC grouprecent IPO
Aardvark Therapeutics, Inc.
AARD
same sectorrecent IPO
Rank One Computing Corp
ROC
nearby deal sizerecent IPO
Jaguar Uranium Corp.
JAGU
nearby deal sizerecent IPO
Wetour Robotics Ltd
WETO
nearby deal sizerecent IPO
Guardian Metal Resources PLC
GMTL
recent IPO
Recent News
No recent news stored for this issuer.